LinkedIn Profile

Access X-ZELL historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:xzell 13405680 Feb 18th, 2020 12:00AM X-ZELL 165 11.00 Open Biotechnology Feb 18th, 2020 02:33PM Feb 18th, 2020 02:33PM X-ZELL is a global biotechnology company specialising in the isolation and visualisation of rare cells won from small blood samples – a process known as liquid biopsy – using a suite of patented and proprietary technologies called hMX Cell Separation™ and Cryoimmunostaining™. Backed by Y Combinator and various high-profile angel investors from around the globe, X-ZELL is best known for the ability to locate tumor-derived Circulating Endothelial Cells (tCEC) – a highly promising biomarker for early cancer detection that has been considered undetectable in routine settings until now. The ability to scan 8-10mL blood samples for the presence or absence of tCEC has allowed X-ZELL to develop a world-unique blood test for patients with suspicion of prostate cancer that is capable of determining the presence or absence of aggressive disease. A 2018 study carried out in Thailand demonstrated that the test, called X-ZELL Prostate™, can prevent more than 70 per cent of unnecessary prostate biopsies in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result. The first in a series of liquid biopsies to be launched over the coming years, X-ZELL Prostate™ is already approved for sale and available in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. A separate 1,000-patient study in Thailand is also underway. More information on www.x-zell.com and via our Twitter handle @XZELLInc Open Biotechnology, Cancer Detection, Liquid Biopsy, Medical Device Development, Immunostaining, Health Technology Open 133 Cecil St, Keck Seng Tower, #06-02 Singapore Singapore SG 069535
private:xzell 13405680 Feb 17th, 2020 12:00AM X-ZELL 163 11.00 Open Biotechnology Feb 17th, 2020 12:50AM Feb 17th, 2020 12:50AM X-ZELL is a global biotechnology company specialising in the isolation and visualisation of rare cells won from small blood samples – a process known as liquid biopsy – using a suite of patented and proprietary technologies called hMX Cell Separation™ and Cryoimmunostaining™. Backed by Y Combinator and various high-profile angel investors from around the globe, X-ZELL is best known for the ability to locate tumor-derived Circulating Endothelial Cells (tCEC) – a highly promising biomarker for early cancer detection that has been considered undetectable in routine settings until now. The ability to scan 8-10mL blood samples for the presence or absence of tCEC has allowed X-ZELL to develop a world-unique blood test for patients with suspicion of prostate cancer that is capable of determining the presence or absence of aggressive disease. A 2018 study carried out in Thailand demonstrated that the test, called X-ZELL Prostate™, can prevent more than 70 per cent of unnecessary prostate biopsies in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result. The first in a series of liquid biopsies to be launched over the coming years, X-ZELL Prostate™ is already approved for sale and available in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. A separate 1,000-patient study in Thailand is also underway. More information on www.x-zell.com and via our Twitter handle @XZELLInc Open Biotechnology, Cancer Detection, Liquid Biopsy, Medical Device Development, Immunostaining, Health Technology Open 133 Cecil St, Keck Seng Tower, #06-02 Singapore Singapore SG 069535
private:xzell 13405680 Feb 16th, 2020 12:00AM X-ZELL 163 11.00 Open Biotechnology Feb 16th, 2020 06:06PM Feb 16th, 2020 06:06PM X-ZELL is a global biotechnology company specialising in the isolation and visualisation of rare cells won from small blood samples – a process known as liquid biopsy – using a suite of patented and proprietary technologies called hMX Cell Separation™ and Cryoimmunostaining™. Backed by Y Combinator and various high-profile angel investors from around the globe, X-ZELL is best known for the ability to locate tumor-derived Circulating Endothelial Cells (tCEC) – a highly promising biomarker for early cancer detection that has been considered undetectable in routine settings until now. The ability to scan 8-10mL blood samples for the presence or absence of tCEC has allowed X-ZELL to develop a world-unique blood test for patients with suspicion of prostate cancer that is capable of determining the presence or absence of aggressive disease. A 2018 study carried out in Thailand demonstrated that the test, called X-ZELL Prostate™, can prevent more than 70 per cent of unnecessary prostate biopsies in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result. The first in a series of liquid biopsies to be launched over the coming years, X-ZELL Prostate™ is already approved for sale and available in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. A separate 1,000-patient study in Thailand is also underway. More information on www.x-zell.com and via our Twitter handle @XZELLInc Open Biotechnology, Cancer Detection, Liquid Biopsy, Medical Device Development, Immunostaining, Health Technology Open 133 Cecil St, Keck Seng Tower, #06-02 Singapore Singapore SG 069535
private:xzell 13405680 Feb 15th, 2020 12:00AM X-ZELL 162 11.00 Open Biotechnology Feb 15th, 2020 12:49AM Feb 15th, 2020 12:49AM X-ZELL is a global biotechnology company specialising in the isolation and visualisation of rare cells won from small blood samples – a process known as liquid biopsy – using a suite of patented and proprietary technologies called hMX Cell Separation™ and Cryoimmunostaining™. Backed by Y Combinator and various high-profile angel investors from around the globe, X-ZELL is best known for the ability to locate tumor-derived Circulating Endothelial Cells (tCEC) – a highly promising biomarker for early cancer detection that has been considered undetectable in routine settings until now. The ability to scan 8-10mL blood samples for the presence or absence of tCEC has allowed X-ZELL to develop a world-unique blood test for patients with suspicion of prostate cancer that is capable of determining the presence or absence of aggressive disease. A 2018 study carried out in Thailand demonstrated that the test, called X-ZELL Prostate™, can prevent more than 70 per cent of unnecessary prostate biopsies in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result. The first in a series of liquid biopsies to be launched over the coming years, X-ZELL Prostate™ is already approved for sale and available in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. A separate 1,000-patient study in Thailand is also underway. More information on www.x-zell.com and via our Twitter handle @XZELLInc Open Biotechnology, Cancer Detection, Liquid Biopsy, Medical Device Development, Immunostaining, Health Technology Open 133 Cecil St, Keck Seng Tower, #06-02 Singapore Singapore SG 069535
private:xzell 13405680 Feb 14th, 2020 12:00AM X-ZELL 162 11.00 Open Biotechnology Feb 14th, 2020 02:37PM Feb 14th, 2020 02:37PM X-ZELL is a global biotechnology company specialising in the isolation and visualisation of rare cells won from small blood samples – a process known as liquid biopsy – using a suite of patented and proprietary technologies called hMX Cell Separation™ and Cryoimmunostaining™. Backed by Y Combinator and various high-profile angel investors from around the globe, X-ZELL is best known for the ability to locate tumor-derived Circulating Endothelial Cells (tCEC) – a highly promising biomarker for early cancer detection that has been considered undetectable in routine settings until now. The ability to scan 8-10mL blood samples for the presence or absence of tCEC has allowed X-ZELL to develop a world-unique blood test for patients with suspicion of prostate cancer that is capable of determining the presence or absence of aggressive disease. A 2018 study carried out in Thailand demonstrated that the test, called X-ZELL Prostate™, can prevent more than 70 per cent of unnecessary prostate biopsies in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result. The first in a series of liquid biopsies to be launched over the coming years, X-ZELL Prostate™ is already approved for sale and available in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. A separate 1,000-patient study in Thailand is also underway. More information on www.x-zell.com and via our Twitter handle @XZELLInc Open Biotechnology, Cancer Detection, Liquid Biopsy, Medical Device Development, Immunostaining, Health Technology Open 133 Cecil St, Keck Seng Tower, #06-02 Singapore Singapore SG 069535
private:xzell 13405680 Feb 13th, 2020 12:00AM X-ZELL 161 11.00 Open Biotechnology Feb 13th, 2020 05:49PM Feb 13th, 2020 05:49PM X-ZELL is a global biotechnology company specialising in the isolation and visualisation of rare cells won from small blood samples – a process known as liquid biopsy – using a suite of patented and proprietary technologies called hMX Cell Separation™ and Cryoimmunostaining™. Backed by Y Combinator and various high-profile angel investors from around the globe, X-ZELL is best known for the ability to locate tumor-derived Circulating Endothelial Cells (tCEC) – a highly promising biomarker for early cancer detection that has been considered undetectable in routine settings until now. The ability to scan 8-10mL blood samples for the presence or absence of tCEC has allowed X-ZELL to develop a world-unique blood test for patients with suspicion of prostate cancer that is capable of determining the presence or absence of aggressive disease. A 2018 study carried out in Thailand demonstrated that the test, called X-ZELL Prostate™, can prevent more than 70 per cent of unnecessary prostate biopsies in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result. The first in a series of liquid biopsies to be launched over the coming years, X-ZELL Prostate™ is already approved for sale and available in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. A separate 1,000-patient study in Thailand is also underway. More information on www.x-zell.com and via our Twitter handle @XZELLInc Open Biotechnology, Cancer Detection, Liquid Biopsy, Medical Device Development, Immunostaining, Health Technology Open 133 Cecil St, Keck Seng Tower, #06-02 Singapore Singapore SG 069535
private:xzell 13405680 Feb 12th, 2020 12:00AM X-ZELL 161 11.00 Open Biotechnology Feb 12th, 2020 02:29PM Feb 12th, 2020 02:29PM X-ZELL is a global biotechnology company specialising in the isolation and visualisation of rare cells won from small blood samples – a process known as liquid biopsy – using a suite of patented and proprietary technologies called hMX Cell Separation™ and Cryoimmunostaining™. Backed by Y Combinator and various high-profile angel investors from around the globe, X-ZELL is best known for the ability to locate tumor-derived Circulating Endothelial Cells (tCEC) – a highly promising biomarker for early cancer detection that has been considered undetectable in routine settings until now. The ability to scan 8-10mL blood samples for the presence or absence of tCEC has allowed X-ZELL to develop a world-unique blood test for patients with suspicion of prostate cancer that is capable of determining the presence or absence of aggressive disease. A 2018 study carried out in Thailand demonstrated that the test, called X-ZELL Prostate™, can prevent more than 70 per cent of unnecessary prostate biopsies in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result. The first in a series of liquid biopsies to be launched over the coming years, X-ZELL Prostate™ is already approved for sale and available in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. A separate 1,000-patient study in Thailand is also underway. More information on www.x-zell.com and via our Twitter handle @XZELLInc Open Biotechnology, Cancer Detection, Liquid Biopsy, Medical Device Development, Immunostaining, Health Technology Open 133 Cecil St, Keck Seng Tower, #06-02 Singapore Singapore SG 069535
private:xzell 13405680 Feb 11th, 2020 12:00AM X-ZELL 161 11.00 Open Biotechnology Feb 11th, 2020 10:58AM Feb 11th, 2020 10:58AM X-ZELL is a global biotechnology company specialising in the isolation and visualisation of rare cells won from small blood samples – a process known as liquid biopsy – using a suite of patented and proprietary technologies called hMX Cell Separation™ and Cryoimmunostaining™. Backed by Y Combinator and various high-profile angel investors from around the globe, X-ZELL is best known for the ability to locate tumor-derived Circulating Endothelial Cells (tCEC) – a highly promising biomarker for early cancer detection that has been considered undetectable in routine settings until now. The ability to scan 8-10mL blood samples for the presence or absence of tCEC has allowed X-ZELL to develop a world-unique blood test for patients with suspicion of prostate cancer that is capable of determining the presence or absence of aggressive disease. A 2018 study carried out in Thailand demonstrated that the test, called X-ZELL Prostate™, can prevent more than 70 per cent of unnecessary prostate biopsies in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result. The first in a series of liquid biopsies to be launched over the coming years, X-ZELL Prostate™ is already approved for sale and available in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. A separate 1,000-patient study in Thailand is also underway. More information on www.x-zell.com and via our Twitter handle @XZELLInc Open Biotechnology, Cancer Detection, Liquid Biopsy, Medical Device Development, Immunostaining, Health Technology Open 133 Cecil St, Keck Seng Tower, #06-02 Singapore Singapore SG 069535
private:xzell 13405680 Feb 10th, 2020 12:00AM X-ZELL 159 11.00 Open Biotechnology Feb 10th, 2020 01:22PM Feb 10th, 2020 01:22PM X-ZELL is a global biotechnology company specialising in the isolation and visualisation of rare cells won from small blood samples – a process known as liquid biopsy – using a suite of patented and proprietary technologies called hMX Cell Separation™ and Cryoimmunostaining™. Backed by Y Combinator and various high-profile angel investors from around the globe, X-ZELL is best known for the ability to locate tumor-derived Circulating Endothelial Cells (tCEC) – a highly promising biomarker for early cancer detection that has been considered undetectable in routine settings until now. The ability to scan 8-10mL blood samples for the presence or absence of tCEC has allowed X-ZELL to develop a world-unique blood test for patients with suspicion of prostate cancer that is capable of determining the presence or absence of aggressive disease. A 2018 study carried out in Thailand demonstrated that the test, called X-ZELL Prostate™, can prevent more than 70 per cent of unnecessary prostate biopsies in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result. The first in a series of liquid biopsies to be launched over the coming years, X-ZELL Prostate™ is already approved for sale and available in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. A separate 1,000-patient study in Thailand is also underway. More information on www.x-zell.com and via our Twitter handle @XZELLInc Open Biotechnology, Cancer Detection, Liquid Biopsy, Medical Device Development, Immunostaining, Health Technology Open 133 Cecil St, Keck Seng Tower, #06-02 Singapore Singapore SG 069535
private:xzell 13405680 Feb 8th, 2020 12:00AM X-ZELL 159 11.00 Open Biotechnology Feb 8th, 2020 05:34PM Feb 8th, 2020 05:34PM X-ZELL is a global biotechnology company specialising in the isolation and visualisation of rare cells won from small blood samples – a process known as liquid biopsy – using a suite of patented and proprietary technologies called hMX Cell Separation™ and Cryoimmunostaining™. Backed by Y Combinator and various high-profile angel investors from around the globe, X-ZELL is best known for the ability to locate tumor-derived Circulating Endothelial Cells (tCEC) – a highly promising biomarker for early cancer detection that has been considered undetectable in routine settings until now. The ability to scan 8-10mL blood samples for the presence or absence of tCEC has allowed X-ZELL to develop a world-unique blood test for patients with suspicion of prostate cancer that is capable of determining the presence or absence of aggressive disease. A 2018 study carried out in Thailand demonstrated that the test, called X-ZELL Prostate™, can prevent more than 70 per cent of unnecessary prostate biopsies in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result. The first in a series of liquid biopsies to be launched over the coming years, X-ZELL Prostate™ is already approved for sale and available in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. A separate 1,000-patient study in Thailand is also underway. More information on www.x-zell.com and via our Twitter handle @XZELLInc Open Biotechnology, Cancer Detection, Liquid Biopsy, Medical Device Development, Immunostaining, Health Technology Open 133 Cecil St, Keck Seng Tower, #06-02 Singapore Singapore SG 069535

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.